Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers

被引:61
作者
Andreu Fernandez, Vicente [1 ,2 ,3 ,4 ]
Almeida Toledano, Laura [3 ,4 ,5 ]
Pizarro Lozano, Nieves [6 ,7 ]
Navarro Tapia, Elisabet [1 ,3 ,4 ]
Gomez Roig, Maria Dolores [3 ,4 ,5 ]
De la Torre Fornell, Rafael [6 ,8 ]
Garcia Algar, Oscar [1 ,4 ,9 ]
机构
[1] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Grp Rec Infancia & Entorn GRIE, Barcelona 08036, Spain
[2] Valencian Int Univ VIU, Dept Nutr & Hlth, Valencia 46002, Spain
[3] Inst Rec Sant Joan Deu IR, SJD, Barcelona 08950, Spain
[4] Inst Salud Carlos III ISCIII, Maternal & Child Hlth & Dev Network 2 SAMID 2, Madrid 28029, Spain
[5] Hosp San Juan Dios, Barcelona Ctr Maternal Fetal & Neonatal Med, BCNatal, Barcelona 08950, Spain
[6] IMIM Hosp del Mar Med Res Inst, Integrat Pharmacol & Syst Neurosci Res Grp, Barcelona 08003, Spain
[7] Autonomous Univ Barcelona, Dept Pharmacol Therapeut & Toxicol, Bellaterra 08193, Spain
[8] Univ Pompeu Fabra CEXS, CIBER Physiopathol Obes & Nutr CIBEROBN, UPF, Barcelona 08002, Spain
[9] Hosp Clin Maternitat, Dept Neonatol, ICGON, IDIBAPS,BCNatal, Barcelona 08028, Spain
关键词
epigallocatechin gallate; EGCG; catechins; polyphenols; green tea; Teavigo((R)); bioavailability; pharmacokinetic profile; antioxidants; food supplement; GREEN TEA POLYPHENOLS; ORAL BIOAVAILABILITY; CANCER PREVENTION; EGCG DERIVATIVES; FISH-OIL; CATECHINS; ANTIOXIDANT; MECHANISMS; (-)-EPIGALLOCATECHIN-3-GALLATE; DEGRADATION;
D O I
10.3390/antiox9050440
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The flavanol epigallocatechin gallate (EGCG) is being tested for the treatment of several diseases in humans. However, its bioavailability and pharmacokinetic profile needs a better understanding to enable its use in clinical trials. There is no consensus on the most appropriate concentration of EGCG in the body to obtain the maximum therapeutic effects. Therefore, the aim of this study is to analyze the bioavailability of EGCG orally administered alone or with different food supplements after overnight fasting in order to determine its optimal conditions (high concentrations in blood and the lowest interindividual variations) to be used as a pharmacological tool in human trials. Ten healthy volunteers (5 men and 5 women) aged 25 to 35 years were recruited prospectively. Three series of clinical experiments with a washout period of seven days among each were performed: (1) Teavigo((R)) (EGCG extract) alone, (2) Teavigo((R)) with a standard breakfast, and (3) FontUp((R)) (Teavigo((R)) commercially prepared with fats, carbohydrates, proteins, vitamins, and minerals). Blood samples were collected at 0, 30, 60, 90, 120, 180, 240, and 360 min after EGCG intake. Free EGCG in plasma was measured using a liquid chromatography and mass spectrometry UPLC-ESI-MS/MS analytical method. The pharmacokinetic variables analyzed statistically were area under the curve (AUC(0-360)), C-max, C-av, C-min, T-1/2, and T-max. EGCG (Teavigo((R))) alone was the group with higher AUC(0-360,) C-max, and C-av both in men (3.86 +/- 4.11 mu g/mL/kg/6 h; 5.95 ng/mL/kg; 2.96 ng/mL/kg) and women (3.33 +/- 1.08 mu g/mL/kg/6 h; 6.66 ng/mL/kg; 3.66 ng/mL). Moreover, FontUp((R)) was the group with the highest value of T-1/2 both in men (192 +/- 66 min) and women (133 +/- 28 min). Teavigo((R)) intake after fasting overnight revealed the highest concentration of EGCG in plasma according to its pharmacokinetic profile, indicating that this is an excellent alternative of administration if the experimental design requires good absorption in the gastrointestinal tract. Moreover, EGCG taken along with food supplements (FontUp((R))) improved the stability of the molecule in the body, being the best choice if the experimental design wants to reduce interindividual variation.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] The catechol-O-methyltransferase inhibitor, tolcapone, increases the bioavailability of unmethylated (-)-epigallocatechin-3-gallate in mice
    Forester, Sarah C.
    Lambert, Joshua D.
    JOURNAL OF FUNCTIONAL FOODS, 2015, 17 : 183 - 188
  • [32] Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats
    Shin, Sang-Chul
    Choi, Jun-Shik
    ANTI-CANCER DRUGS, 2009, 20 (07) : 584 - 588
  • [33] Bilosomes as effective delivery systems to improve the gastrointestinal stability and bioavailability of epigallocatechin gallate (EGCG)
    Wang, Li
    Huang, Xin
    Jing, Huijuan
    Ma, Chaoyang
    Wang, Hongxin
    FOOD RESEARCH INTERNATIONAL, 2021, 149
  • [34] (-)-Epigallocatechin gallate as an inhibitor of hemoglobin-catalyzed lipid oxidation: molecular mechanism of action and nutritional application
    Li, Jia-Xin
    Lu, Naihao
    Tian, Rong
    TOXICOLOGY IN VITRO, 2024, 99
  • [35] Effect of of (-)-epigallocatechin gallate at different pH conditions on enteric viruses
    Falco, Irene
    Randazzo, Walter
    Gomez-Mascaraque, Laura
    Aznar, Rosa
    Lopez-Rubio, Amparo
    Sanchez, Gloria
    LWT-FOOD SCIENCE AND TECHNOLOGY, 2017, 81 : 250 - 257
  • [36] Encapsulation of epigallocatechin-3-gallate into albumin nanoparticles improves pharmacokinetic and bioavailability in rat model
    Nithya Ramesh
    Abul Kalam Azad Mandal
    3 Biotech, 2019, 9
  • [37] BIOAVAILABILITY OF NAFARELIN IN HEALTHY-VOLUNTEERS
    CHAPLIN, MD
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (02) : 762 - 765
  • [38] Nanolipidic particles improve the bioavailability and α-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease
    Smith, Adam
    Giunta, Brian
    Bickford, Paula C.
    Fountain, Michael
    Tan, Jun
    Shytle, R. Douglas
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 389 (1-2) : 207 - 212
  • [39] Relative Bioavailability of Orally Administered Fosphenytoin Sodium Injection Compared with Phenytoin Sodium Injection in Healthy Volunteers
    Kaucher, Kevin A.
    Acquisto, Nicole M.
    Rao, Gauri G.
    Kaufman, David C.
    Huntress, Jeff D.
    Forrest, Alan
    Haas, Curtis E.
    PHARMACOTHERAPY, 2015, 35 (05): : 482 - 488
  • [40] Epigallocatechin-3-gallate and postprandial fat oxidation in overweight/obese male volunteers: a pilot study
    Thielecke, F.
    Rahn, G.
    Boehnke, J.
    Adams, F.
    Birkenfeld, Al
    Jordan, J.
    Boschmann, M.
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2010, 64 (07) : 704 - 713